UY29346A1 - 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2-fenil-indoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
UY29346A1
UY29346A1 UY29346A UY29346A UY29346A1 UY 29346 A1 UY29346 A1 UY 29346A1 UY 29346 A UY29346 A UY 29346A UY 29346 A UY29346 A UY 29346A UY 29346 A1 UY29346 A1 UY 29346A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutically acceptable
prostaglandina
indoles
antagonists
receptor
Prior art date
Application number
UY29346A
Other languages
English (en)
Inventor
Keith John Harris
Hans-Jochen Lang
Rose Mappilakunnel Mathew
Stephen James Shimshock
Thaddeus R Nieduzak
Sharon Jackson
Zhaoxia Yang
Kenneth Bordeau
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY29346A1 publication Critical patent/UY29346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga un compuesto de la fórmula (XVI) en la que R, R2, R3, R4, R5, R6, R7, y n son como se definen en la Memoria Descriptiva, o una de sus sales, hidratos o solvatos farmacéuticamente aceptables, uno de sus profármacos farmacéuticamente aceptables, o una sal, hidrato o solvato del profármaco farmaceticamente aceptable, una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de uno o más compuestos según la fórmula (XVI) en mezcla con un vehiculo farmacéuticamente aceptable, un método para tratar a un paciente que sufre un trastorno mediano por la PGD2.
UY29346A 2005-01-26 2006-01-26 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 UY29346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64730705P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
UY29346A1 true UY29346A1 (es) 2006-08-31

Family

ID=36282872

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29346A UY29346A1 (es) 2005-01-26 2006-01-26 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20070265278A1 (es)
EP (1) EP1844011A1 (es)
JP (1) JP2008528606A (es)
KR (1) KR20070110277A (es)
CN (1) CN101146770A (es)
AR (1) AR054726A1 (es)
AU (1) AU2006209213A1 (es)
BR (1) BRPI0607079A2 (es)
CA (1) CA2595728A1 (es)
CR (1) CR9214A (es)
DO (1) DOP2006000016A (es)
GT (1) GT200600030A (es)
IL (1) IL184816A0 (es)
MA (1) MA29259B1 (es)
MX (1) MX2007008277A (es)
NO (1) NO20074336L (es)
PA (1) PA8661201A1 (es)
PE (1) PE20060878A1 (es)
RU (1) RU2007132166A (es)
SG (1) SG158918A1 (es)
TN (1) TNSN07251A1 (es)
TW (1) TW200639151A (es)
UY (1) UY29346A1 (es)
WO (1) WO2006081343A1 (es)
ZA (1) ZA200705449B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2066628E (pt) * 2006-07-25 2010-12-31 Sanofi Aventis 2-fenil-indoles como antagonistas do receptor da prostaglandina d2
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
WO2009061730A2 (en) * 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
MY183111A (en) 2010-03-22 2021-02-15 Idorsia Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2626349A4 (en) * 2010-10-06 2014-03-12 Kureha Corp AMINE CONNECTION AND ITS USE
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
TW201318624A (zh) * 2011-09-29 2013-05-16 Shionogi & Co 包含ｐｇｄ２拮抗劑及組織胺拮抗劑之過敏性鼻炎治療用醫藥
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6168520B2 (ja) * 2013-09-17 2017-07-26 国立大学法人 千葉大学 インドール化合物、ｄｐプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びｄｐプロスタノイド受容体アンタゴニストの使用。
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
WO2015140684A1 (en) 2014-03-17 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
SG11202002065VA (en) 2017-09-13 2020-04-29 Progenity Inc Preeclampsia biomarkers and related systems and methods
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113173877B (zh) * 2020-10-30 2023-10-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法
CN115925606B (zh) * 2023-01-05 2023-10-13 宁夏医科大学 一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496844A (en) * 1992-05-08 1996-03-05 Otsuka Pharmaceutical Factory, Inc. Indole derivatives
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
JP2004024655A (ja) * 2002-06-27 2004-01-29 Aruze Corp 遊技機
WO2004078719A1 (ja) * 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0511834A (pt) * 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Also Published As

Publication number Publication date
PA8661201A1 (es) 2006-09-08
IL184816A0 (en) 2007-12-03
CA2595728A1 (en) 2006-08-03
CR9214A (es) 2007-11-23
US20070265278A1 (en) 2007-11-15
KR20070110277A (ko) 2007-11-16
PE20060878A1 (es) 2006-10-18
ZA200705449B (en) 2009-01-28
MX2007008277A (es) 2007-09-07
MA29259B1 (fr) 2008-02-01
AR054726A1 (es) 2007-07-11
TNSN07251A1 (en) 2008-12-31
EP1844011A1 (en) 2007-10-17
NO20074336L (no) 2007-10-23
TW200639151A (en) 2006-11-16
WO2006081343A1 (en) 2006-08-03
GT200600030A (es) 2006-09-27
RU2007132166A (ru) 2009-03-10
JP2008528606A (ja) 2008-07-31
AU2006209213A1 (en) 2006-08-03
BRPI0607079A2 (pt) 2009-08-04
CN101146770A (zh) 2008-03-19
DOP2006000016A (es) 2006-07-31
SG158918A1 (en) 2010-02-26

Similar Documents

Publication Publication Date Title
UY29346A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
UY30283A1 (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
RS53293B (en) CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THERAPY
PE20080827A1 (es) N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2
PH12017501326A1 (en) Tgf-� inhibitors
AR092284A1 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDROGENOS (SARMs) Y USOS DE LOS MISMOS
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CO6180503A2 (es) Composiciones de inhibidores de chk1
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
CL2011002433A1 (es) Compuestos tetraciclicos, inhibidores de alk; composicion farmaceutica que comprende dichos compuestos, utiles en la profilaxis o el tratamiento de cancer, metastasis de cancer, depresion o un trastorno de la funcion cognitiva.
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
RS52245B (en) CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
CR20110616A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
CO6290763A2 (es) Derivados de benzamidas, carboxamidas y nicotinamidas como moduladores alostericos positivos y sus composiciones
CR10540A (es) Derivados ciclopropil amina
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4